Editorial: Window dressing
By Sacramento Bee,
Sacramento Bee
| 06. 23. 2005
Stem cell 'enhancements' won't do the job
As part of a closed-door deal with the state Senate, leaders of California's $3 billion stem cell institute have proposed some revisions to their weak policies on conflicts of interest, open meetings and public access to internal documents.
These proposals, while a step forward, are a mixed bag. On one hand, they don't go far enough in preventing $3 billion in public monies from being directed to interests with inside access at the Institute for Regenerative Medicine. On the other, they demonstrate that public pressure can prompt this agency to revisit how it does business.
The main issue centers on the out-of-state researchers and industry employees who will be recommending millions of dollars in stem cell research grants to California universities, nonprofits and industries.
Right now, the public knows the identities of these peer reviewers, but not whether they have side deals with biomedical firms or stock in Geron or other corporations interested in stem cell research. That's because the peer reviewers are not required to publicly disclose their economic interests, as do...
Related Articles
By Tomoko Otake, The Japan Times | 04.09.2024
A decade ago, researcher Haruko Obokata caused a sensation when she published two papers in the journal Nature, in which she claimed that she had discovered a way to create stem cells easily using the so-called STAP method.
With STAP...
By Ian Sample, The Guardian | 03.08.2024
Scientists are a step closer to making IVF eggs from patients’ skin cells after adapting the procedure that created Dolly the sheep, the first cloned mammal, more than two decades ago.
The work raises the prospect of older women being...
By Ramon Antonio Vargas, The Guardian | 02.28.2024
Doctors say a man in California who contracted blood cancer while living with HIV is in remission from both potentially fatal illnesses thanks to a treatment they are hailing as remarkable and encouraging.
Paul Edmonds is only the fifth-known person...
By Victoria Gray, Uduak Thomas, and Kevin Davies, The CRISPR Journal | 02.14.2024
In July 2019, medical staff in Nashville dosed the first U.S. patient in the exa-cel therapy trial, sponsored by Vertex Pharmaceuticals and CRISPR Therapeutics. That first patient was Victoria Gray, a mother of four from Forest, Mississippi, a sickle cell...